Valeritas — Investor Presentation (July 2016)
30 slides from Valeritas's investor presentation, Jul 12, 2016
Slide 1: Investor Presentation July 2016
Exhibit 99.1 Actual DELIVERING Investor John July ART-920 2016 Timberlake, V-Go® Presentation Rev: A Patient QUALITY President OF & CEO LIFE
Slide 2: Forward-Looking Statements
Forward stated “Valeritas,” This future reasonable and “would”, “expect,” except events Our competitive manufacturing efficiently 2our history dependence inability failure liquidity. materially estimates, presentation in events or tothis Looking the ”“plan” other increase to assumptions “will,” of “
Slide 3: Compelling Investment Case for Valeritas
Compelling Valeritas: Large Key New Commercial Efficient Traction Removed Opportunity $15B market Established ~80% diabetes on versus ~3M >8% manufacturing ~12M management 3A1C insulin Risks A1C Capital goal refers patients U.S. Market of units insulin potential patients Type Model of not Commercial
Slide 4: V-Go: Only FDA-cleared Disposable Insulin Delivery Device
V-Go® Only Specifically Small, Convenient 4Reimbursed FDA-cleared discreet, Insulin drug-like designed at the Delivery: disposable pharmacy single-use, distribution to address The and –Ideal fully where easy-to-use unmet model Device disposable Type needs For 2 patients ininsulin Patients Type go2de
Slide 5: Experienced Corporate Leadership Team
TheCorporate Extensive Years Industry John President Geoffrey EVP Matt SVP Mark 5VP Valeritas Commercial Manufacturing, Timberlake Nguyen Conley of Experience /Jenkins &Valeritas and Chief Leadership 21 30 Controller Proven /26 30 410 Executive //Operations, 10 7Track & Team Treasurer Record Officer
Slide 6: Strengthened Commercial Strategy
Strengthened, 1Q15 COMMERCIAL STRATEGY SALES Low REP geographic CAPACITY MANUFACTURING OPERATING 6LOSSPRODUCTIVITY productivity $(15.7)M 1Q16 TERRITORIES dispersion ~12M &Focused, Capital-intensive $(9.6)M Broad due Units toCapital-Efficient territory U.S. ~64 rapid ~16M~27 Focus Driving Units expan
Slide 7: Large Type 2 Diabetes Market Opportunity
Key The TOTA ~22 not 80% (4.6 90-95% Type 5-10% (1) A1C months average to Figures Grabner Res. wholesalers. Based atmillion 4.6 million) Differentiator: 2013 refers 2A1C 1 LOpportunity(1) xapproximate. Million blood M, D4.6 on Sep Igoal to Chen ~5.8 AV-Go® M aglucose 23;5:471-9. GThe blood Patients
Slide 8: Type 2 Patients Require Mealtime Insulin
Patients Mealtime 250 Type (mg/dL) 100 Plasma 50 Glucose 06AM Time 82% (1) (2) Adapted 200 Holman of 2of 12PM Diabetes Patients Day with Levels 150 / Prandial RR from: 6PM Type Elevated et with Normal Hyperglycemia 12AM Glucose al. Riddle. 2 Diabetes Type NBasal Engl 6AM Basal Diabetes Levels 2 Diab
Slide 9: Complexity Is a Barrier; V-Go Offers Simplicity
Complexity ~75% V—Go® Simplicity Data Custom from Patients Research SOLVE U.S. Ease-of-use andPrescribed Roper ofLLC. SLack UNME Diabetes Discretion This of? Discretion 3Tstudy Shots/Day PATI Patient isEan NT can Market annual Do NE Result Not Estudy survey DS: Inject in Non-Compliance provided of I
Slide 10: Revolutionizing Mealtime Insulin Treatment
Revolutionizing Discreet No Simple Easy Daily Convenient As Cost 10 easy audible need Effective todisposable training Use as toMealtime prescription carry alerts Access Noprocess Type Cost supplies /programing, daily dosing Available neutral 2 medication Insulin routine / No bytobatteries, needles c
Slide 11: V-Go Addresses Key Unmet Needs
Addresses V-Go® Programmable Physiologic Intensive Simple >95% Premix or Basal 11 Nonphysiologic +1 on ofComplex provides Type Insulin Therapy Key2Pump Unmet Patients both background Needs for Type & mealtime 2 Patients insulin in a simple-to-use device
Slide 12: V-Go Simple Step Delivery
Confidential V-Go® Preset insulin constant On-demand coverage Activate 1Step Delivery Bolus 122 Step Delivery Bolus Ready basal delivered : rate Bolus Combines Button in Bolus 2insulin rates –Button units/click Button Not Ready at of Step For afor Simplicity 3Button Bolus mealtime Distribution and D
Slide 13: Strong Clinical Data Supports Adoption
Strong 21Statistically Papers Clinical patients ~700 43Lowered 34 (1) Meetings Medical al. Diabetes Improvements Improved (Prescribed Demonstrated Poster Rosenfeld and studied Ther. Total presented Extensive Quality Significant /CR, Administered)(1-6) 2015;6 Daily Cost inet A1C(1-6) at ofal. Insulin
Slide 14: Better Glycemic Control Improves Health
Better43% Significant Each reduces Deaths 21% Microvascular Complications 37% Stratton 14 14% 1% Glycemic from risk IMreduction Adverse et for Diabetes al. Peripheral Disease Control BMJ. inHealth mean Heart 2000;321:405-412. Improves Vascular Effects A1C AttacksInfluenced and ExtendsbyLives Poor Gl
Slide 15: Robust A1C Reductions Across Studies
Robust SIMPLE(1) Basal 9BL: A1C in Change -1.8 -1.5 -2.4 Clinically BL= -3.4 Grunberger Omer, Rosenfeld Sandberg, Lajara, Lajara N’s 15Months =SIMPLE-59, 8.7% Baseline -1.0 Cohort A. R, et Clinical et Davidson al. -2.0 ~7 BL: Relevant M, CR, -1.2 G, al. DA(2) Poster Months Vs. -2.3 Martinez, 9.5% et
Slide 16: Switching to V-Go Reduced Total Daily Insulin Dose
Switching Jones SIMPLE(1) Baseline Insulin in -22% Change Grunberger, -46% -41% % Omer, Data Sink Lajara *Change 16 -18% JH on -20% Diabetes A. R,file. et62 in et Davidson to al. basal al. UUMASS(2) G, V-Go® Poster TDD Poster Diabetes et-13% -28% component al.JA, 119 presented Poster Demonstrated pr
Slide 17: V-Go Reduces A1C and Insulin Use
V-Go® Key 140 120 119 10.0 100 (units) TDD 80 60 Insulin 40 20 0Change †Pre N=14 (1) Omer, UMASS P=0.01, -55 Based V-Go Benefit —55U Average A. -2.4U 64† Significantly =Study et on *P=0.001 46%(1) 6.0 On al. 8.0 to Insulin 11.0 10.7 —2.4 A1C Duration Poster Both V-Go . 7.0 8.3* (%) Patients TDD Redu
Slide 18: V-Go vs MDI: Better A1C with Less Insulin
V-Go® Better 10.0 9.0 80 9.5 90 8.4* (%) A1C 60 7.7* 7.5 50 6.5 7.0 40 7.6* Baseline V-Go V-Go: MDI: Data Lajara 8.5 P<0.0001 are 8.0 P=0.02 MDI N=60 Control N=56 TDD 27 R, Demonstrates MDI mean 12 Davidson 70week BL BL weeks 30 8.1* (U/day) with (SE) A1C- A1C- 27 atLess JA, week 9.4%, Significant 9
Slide 19: V-Go More Cost-Effective Therapy vs MDI
V-Go® †V-Go $217.16 $250 Month Per Cost Pharmacy $100 Direct MDI $0 †P-value Insulin and as Lajara 19P=0.013 ofin multiplying reduction 9/1/2015. V-Go Reduced Per R, A1C costs iscalculated Davidson a1% $50 More $200 include $150 Direct the Cost-Effective JA, monthly using both Pharmacy $118.84 et th
Slide 20: Patients Report Convenience and Quality of Life
Patients 53% 80% 90% Convenience(1) (1) Note: Quality Respondents 50% 60% 70% Survey 30% 6% 20% 0% 10% 44% 29% Prior Therapy How 20 Data Very 10% 28% Generally do V-Go Excellent Patients Good 20% of Rate you on Therapy 27% Life(2) File Convenient feel 40% the Convenient were (Valeritas physically Co
Slide 21: V-Go Competition and Reimbursement Advantages
V-Go® V-Go Reimbursement Technology Distribution Daily Programmable Pricing Training Insulin Competition Syringes Simplicity, Roche 21 has for Disposable Pens Pay-as-You-Go vs. Burden Type Numerous J&J Traditional Cost, Mechanical Electronic 2Animas /Low Convenience, Pharmacy / ype Durable Advantage
Slide 22: V-Go Sold Through Pharmacy Distribution
V-Go® Type V-Go ~90% Sold Enhanced Traditional Durable Requires Equipment Annual Monthly 22 at 2Type for Distribution Patients Pharmacy Medical isMedical Medical Medical Type Accessible Patient 1Co-pay Pump 2Generally Deductibles Diabetes Convenience Co- /Necessity Through Retail at Maker and Pharma
Slide 23: Pharmacy Reimbursement Model Is Cost Neutral
Pharmacy Basal/Bolus Neutral (~$20/day) V-Go® $31 $73 co-pay *What when$31 V-Go aco-pay Therapy Cost Payor Neutral Benefit $11 between Contracted Pen to $62 co-pay $31 Pays Payors Therapy Cost or Reimbursement orRegimens* (Net $84 $53 co-pay1 toinPatients of Preferred $31 Rebates co-pay (+/- Model P
Slide 24: Established Access for Commercial Lives
Established 70%+ < of Not or Access V-Go Under 164 Insurance 34 Diabetes Over TRICARE *All Commercial 30% Lives Restricted MAccess Covered M90% Total Covered Commercial Exception Pharmacy <of70%+ 40% Prevalence Lives of & figures Lives* Reimbursement Pharmacy Formulary V-Go State Pharmacy Medical No
Slide 25: Extensive V-Go Patient Experience
Extensive V-Go® V-Go 7Source: 13525Million adherence product Symphony Patientquality &Experience persistency Health validated Solutions With better with Proven (Retail than >7 million most Quality andType Mail devices 2Order). regimens used clinically (injections or pills)
Slide 26: Multi-Layered Scalable Business Growth Strategy
Multi-Layered Scalable 26 Business Growth Model Strategy
Slide 27: Focused Commercial Strategy
Newly Target prescribing physicians Focused contact HCP’s HCP – high on Healthcare Focused Ensure pharmacy of frequency Increase office and marketing Professionals, Capital model optimal and Efficient access which andCommercial patient includepatient Prescribers, Strategy support Physician selection
Slide 28: Revised Sales Model Driving Rep Productivity
Revised Top 3rd Rep Month Sales Low /TRx Focus Vacated territories Utilize Increase Weekly Inside Third Focused Targeted Minimize Greater Less 28 Inside Party performing performing capital Party on sales Cust. fewer & calls Commercial prescriber promotional direct fewer DTP Services prescription str
Slide 29: Valeritas: Poised for Growth and Profitability
Valeritas: Poised Annual Revenue $18.1 $13.5 34% Greater on Productivity 118% $6.2 Basis Reduction Significant Cash NM $0.6 2012 COGS Gross Margins *Other 29 a ~per reps 2013 Burn 2013 64 for highly Patch Revenue Sales Negative ($ sales reps Financial Growth inin 2015 2014 Pump dependent With reps m
Slide 30: Significantly De-Risked, Advancing Growth Opportunities
Significantly Advancing Bolus 510(k) Regulatory Clinical EU Cost-Effectiveness >70% Reimbursement Prescriber TRICARE Patient Manufacturing ~8M Growth U.S. Focus Targeted Early Continued “wins” International Next Platform Other ART-920 30 Units Generation 2017 therapeutics Insulin on promotion commer
Valeritas Holdings — Investor Presentation (July 2016) on 6ix